Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
32 hedge funds and large institutions have $2.58M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 43 closing their positions.
2,462% more call options, than puts
Call options by funds: $538K | Put options by funds: $21K
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
52% less funds holding
Funds holding: 67 → 32 (-35)
63% less capital invested
Capital invested by funds: $7M → $2.58M (-$4.43M)
81% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 43
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$1.05M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.02M |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$617K |
| 4 |
Morgan Stanley
New York
|
+$475K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.17M |
| 2 |
GJL
Gendell Jeffrey L
|
-$435K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$133K |
| 4 |
Millennium Management
New York
|
-$55.8K |
| 5 |
SWA
Stratos Wealth Advisors
Beachwood,
Ohio
|
-$53K |
SEEL Hedge Fund Activity: Q4 2023 in Review
32 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2023, worth a combined $2.58M — down 63% from $7M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of SEEL and 8 opened new positions — a net loss of 35 holders — while 7 trimmed existing stakes and 11 added.
The largest buyer was Mirae Asset Global Investments, adding an estimated $1.05M. The largest seller was Sabby Management, exiting entirely with an estimated $2.17M sold.
- 32 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2023, down from 67 in Q3 2023.
- Funds reported $2.58M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2023, down 63% quarter-over-quarter.
- 8 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2023 and 43 closed out, a net change of -35 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2023 was Mirae Asset Global Investments, an estimated $1.05M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2023 was Sabby Management, an estimated $2.17M sold.
Based on aggregated 13F filings for Q4 2023.